Related Experiment Video
Updated: Feb 7, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
Published on: October 3, 2018
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for
Christopher B Benton1, Maliha Khan1, David Sallman2
1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
The International Prognostic Scoring System-Revised (IPSS-R) is one standard for myelodysplastic syndrome (MDS) risk stratification. It divides patients into five categories including an intermediate subset (IPSS-R int-risk). Outcomes and clinical interventions for patients with IPSS-R int-risk are not well defined. We performed an analysis of outcomes of this group of patients. Out of 3167 patients, a total of 298 were identified with IPSS-R int-risk MDS and retrospectively analyzed to assess characteristics affecting outcomes. Cox proportional hazard models for overall survival (OS) were performed to identify statistically significant clinical factors that influence survival. Age of 66 years or greater, peripheral blood blasts of 2% or more, and history of red blood cell (RBC) transfusion were significantly associated with inferior survival. Based on these features, MDS patients with IPSS-R int-risk were classified into two prognostic risk groups for analysis, an int-favorable group and an int-adverse group, and had significantly divergent outcomes. Sequential prognostication was validated using two independent datasets comprising over 700 IPSS-R int-risk patients. The difference in median survival between int-favorable and int-adverse patients was 3.7 years in the test cohort, and 1.8 and 2.0 years in the two validation cohorts. These results confirm significantly variable outcomes of patients with IPSS-R int-risk and need for different prognostic systems.
Insights
The International Prognostic Scoring System-Revised (IPSS-R) intermediate-risk myelodysplastic syndromes (MDS) have variable outcomes. Age, blasts, and RBC transfusions define distinct int-favorable and int-adverse groups with different survival.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- The International Prognostic Scoring System-Revised (IPSS-R) is a standard for myelodysplastic syndromes (MDS) risk stratification.
- The intermediate-risk (IPSS-R int-risk) subset of MDS patients has poorly defined outcomes and treatment strategies.
Purpose of the Study:
- To analyze outcomes for patients with IPSS-R int-risk MDS.
- To identify clinical factors influencing survival in this patient group.
- To develop a refined prognostic model for IPSS-R int-risk MDS.
Main Methods:
- Retrospective analysis of 298 IPSS-R int-risk MDS patients from a cohort of 3167.
- Cox proportional hazard models used to identify significant prognostic factors for overall survival (OS).
- Validation of a new prognostic classification using two independent datasets (>700 patients).
Main Results:
- Age (≥66 years), peripheral blood blasts (≥2%), and red blood cell (RBC) transfusion history were associated with inferior survival.
- Patients were classified into int-favorable and int-adverse groups with significantly divergent outcomes.
- Median survival differences between groups ranged from 1.8 to 3.7 years across cohorts.
Conclusions:
- Outcomes for IPSS-R int-risk MDS patients are highly variable.
- A refined prognostication system stratifying patients into int-favorable and int-adverse groups is needed.
- This study provides a validated model for improved risk stratification in intermediate-risk MDS.
Related Concept Videos
The Intermediate Value Theorem
Disassembly of Intermediate Filaments
Keratin proteins, found at the cell periphery near cell junctions, undergo a cycle of assembly and disassembly. In Type...
Types of Intermediate Filaments
Formation of Intermediate Filaments
The Structure of Intermediate Filaments
Intermediate...
Predicting Reaction Outcomes

